Ms. Yingying Yang is a Principal of Quan Capital based at the firm’s Shanghai office. Prior to joining Quan in 2017, Ms. Yang was with Sanofi China’s strategy planning group, focusing on internal pipeline prioritization and external licensing / M&A strategy. Before Sanofi, she served as associate consultant at LEK consulting, focusing on healthcare and particularly pharmaceutical sector.
Ms. Yang received her Bachelor in Economics from Fudan University, and a MSc of Finance from Imperial College London. She also obtained a dual Bachelor degree in Pharmacology from Shanghai Jiaotong University, School of Medicine when she’s at Quan.
Ms. Yang currently serves on the board of Oricell Therapeutics and Kira Pharmaceuticals. She also serves as a board observer of Eluminex Biosciences, Innoforce, RareStone Group, MEDx, and deeply involved in Quan’s investments of Laronde.